Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc. reports developments tied to its robotic surgery technology, financial results, and public-company status. The company is developing the Vicarious Surgical System for minimally invasive surgery, with updates covering benchtop and in-vivo testing, surgical instruments for ventral hernia repair, software engineering support, and progress toward system validation and clinical readiness.
Company news also covers operating expense trends, research and development spending, cash-burn discipline, and capital markets actions involving its Class A common stock. Recent disclosures include quotation on the OTCQB market after NYSE suspension and filings related to stockholder approval of a potential reverse stock split.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its third quarter 2021 financial results, marking its entry into public markets. The company posted an operating expense of $8.6 million, a 156.2% increase from the previous year. R&D expenses rose to $5.2 million while general and administrative costs increased to $2.5 million. The net loss reached $65.5 million, showing a significant increase from $3.3 million in Q3 2020, resulting in a net loss per share of $0.71. However, cash reserves stood strong at $185 million as of September 30, 2021.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will present at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 18 at 4:00 p.m. Eastern Time. The management will also engage in virtual investor meetings throughout the day. The presentation will be live-streamed on the Company’s website, with an archive available afterward. Vicarious Surgical specializes in innovative robotics technology aimed at enhancing surgical efficiency and patient outcomes.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced management's participation in the Credit Suisse 30th Annual Healthcare Conference on November 11 at 3:30 p.m. ET. The company aims to enhance surgical procedures' efficiency and patient outcomes through its innovative robotics technology. A live webcast of the presentation will be available on the company’s website, with an archive accessible post-conference. Vicarious Surgical, founded in 2014, has developed a groundbreaking surgical system recognized by the FDA with Breakthrough Device Designation.
Vicarious Surgical Inc. (NYSE: RBOT) will announce its third quarter 2021 financial results on November 8, 2021, after market close. A conference call will follow at 4:30 p.m. ET. The company focuses on enhancing surgical procedures through innovative robotics technology, aiming to improve patient outcomes while lowering costs. Vicarious Surgical's system, which combines human-like robots and virtual reality, has received FDA's Breakthrough Device Designation, marking a significant achievement in surgical technology.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced a long-term lease for an additional 30,000 square feet in Waltham, MA, expanding its manufacturing capacity. This new facility will feature four operating rooms for research and testing, enhancing development and hospital engagement. CEO Adam Sachs emphasized that this expansion is vital for innovation and commercialization of their robotics technology aimed at improving surgical efficiency and patient outcomes. Established in 2014, Vicarious Surgical is known for its FDA-designated Breakthrough Device for minimally invasive surgeries.
Vicarious Surgical Inc. (NYSE: RBOT) celebrated its public listing by ringing the closing bell at the New York Stock Exchange on September 21, 2021. The company's merger with D8 Holdings Corp. was completed on September 17, 2021, and trading began on September 20, 2021. Vicarious Surgical aims to enhance surgical procedures' efficiency and patient outcomes using advanced robotics and virtual reality technology. The firm's innovative surgical approach has received FDA Breakthrough Device Designation, marking a significant milestone in minimally invasive surgical robotics.
Vicarious Surgical Inc. and D8 Holdings Corp. have reached a definitive business combination agreement, transitioning Vicarious to publicly trade under the new ticker symbol RBOT post-closing on the NYSE. This merger aims to enhance surgical efficiency and patient outcomes through Vicarious's advanced robotics technology, which provides significant cost savings compared to legacy systems. The transaction could yield up to $460 million in gross proceeds, supported by a $115 million private placement. The merger is anticipated to finalize by Q3 2021, pending D8 shareholder approval.